1 not yet recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow Alpha-1 Antitrypsin Deficiency-associated Lung Disease: new trials by email Literature Review of Alpha-1 Antitrypsin Deficiency-associated Lung Disease trials Research Report on Alpha-1 Antitrypsin Deficiency-associated Lung Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency PM647a - Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease | Phase 1 / Phase 2 | Not yet recruiting | Prime Medicine, Inc. | 54 | 2026-10-01 | 2026-10-21 |
| NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biological NTLA-3001 - Lung Disease, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Intellia Therapeutics | 2024-11-20 | 2025-01-17 |
alpha 1-Antitrypsin Deficiency (2) · Lung Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Emphysema (2) · Genetic Diseases, Inborn (2) · Liver Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Subcutaneous Emphysema (2) · Lung Diseases (1)
Intellia Therapeutics (1) · Prime Medicine, Inc. (1)
New Zealand (1)